Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Twelves, C. J.
Right arrow Articles by Rubens, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Twelves, C. J.
Right arrow Articles by Rubens, R. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 2:663-666, 1991
© 1991 European Society for Medical Oncology

research-article

Original article: Epirubicin in breast cancer patients with liver metastases and abnormal liver biochemistry: Initial weekly treatment followed by rescheduling and intensification

C. J. Twelves, M. A. Richards, P. Smith and R. D. Rubens

Imperial Cancer Research Fund Department of Clinical Oncology, United Medical and Dental Schools, Guy's Hospital London, U.K.

Correspondence to: Dr C. J. Twelves, I.C.R.F. Clinical Oncology Unit, Guy's Hospital, St Thomas Street, London SE1 9RT, U.K.

Fifty-two consecutive patients with breast cancer and liver metastases have been treated with epirubicin. All had a serum aspartate aminotransferase more than twice the upper limit of normal or a raised bilirubin. Initial treatment was with 6 cycles of weekly epirubicin 25 mg/m2. In patients whose liver biochemistry improved sufficiently, treatment was then changed to a 3-weekly schedule and an attempt was made to increase dose-time intensity during a further 6 cycles of epirubicin. The UICC response rate was 15/52 (29%, with 95% confidence intervals 18-42%) and median response duration was 34 weeks. All 23 patients who were eligible for rescheduling received epirubicin 3-weekly, but escalation of dose intensity was possible in only 5 patients. The activity and tolerability of weekly epirubicin has been confirmed in patients with liver metastases from breast cancer. However, late dose escalation was impracticable in the majority of patients and did not appear to improve outcome.

breast cancer, liver metastases, epirubicin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 GutHome page
G B McDonald and D Frieze
A problem-oriented approach to liver disease in oncology patients
Gut, July 1, 2008; 57(7): 987 - 1003.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.